Objective: To describe the quality of life (QoL) of breast cancer patients treated with adjuvant chemotherapy following radical breast cancer surgery at K Hospital in 2024.
Subjects and Research Methods: A prospective descriptive study was conducted from April 2024 to November 2024 with 85 early-stage breast cancer patients who received adjuvant chemotherapy after radical surgery. Quality of life scores were assessed using the EORTC QLQ-30 and QLQ-BR23 scales from the European Organization for Research and Treatment of Cancer. QoL was evaluated at different time points before chemotherapy and after treatment.
Results:
- QLQ-30 QoL Scores at the time of treatment completion: The overall QoL score was 67.5, with social functioning having the highest score (86.7) and physical functioning the lowest (75.3). The general symptom domain scored 23.2, with the most bothersome symptoms being fatigue (35.6), pain (29.4), and loss of appetite (28.3). Financial impact was also a significant concern, with a score of 27.6.
- QLQ-BR23 Scores at the time of treatment completion: The future perspective scored the highest at 66.8. In terms of symptom domains, systemic side effects scored 24.3, arm symptoms 15.6, and breast symptoms 12.8. Statistically significant differences in QoL, both in functioning and symptoms, were observed between patients before treatment, after 3-4 cycles, and after completing treatment.
Conclusion: These findings provide multidimensional insights into the side effects and toxicity of chemotherapy, as well as the physical and mental health of patients during treatment. This information can guide appropriate communication strategies, emotional support, and assist patients in developing optimal treatment plans.